drugset / Trial / NCT01958164

Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion

NCT01958164

Phase 3 Completed 16 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD

Timeline

Start
2013-09
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 2 mg Other

Indications

No indication recorded.